In Q1, Shattuck Labs (NASDAQ:STTK) posted sales of $2.27 million. Earnings were up 3.43%, but Shattuck Labs still reported an overall loss of $12.42 million. In Q4, Shattuck Labs brought in $1.34 million in sales but lost $12.01 million in earnings.
Shattuck Labs, Inc. (Shattuck) (NASDAQ:STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients